Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Chromatin/Epigenetics

Chromatin/Epigenetics

Chromatin/Epigenetics

Epigenetics

Epigenetics means above genetics. It determines how much and whether a gene is expressed without changing DNA sequences. Epigenetic regulations include, 1. DNA methylation: the addition of methyl group to DNA, converting cytosine to 5-methylcytosine, mostly at CpG sites; 2. Histone modifications: posttranslational modificationEpigeneticss of histone proteins including acetylation, methylation, ubiquitylation, phosphorylation and sumoylation; 3. miRNAs: non-coding microRNA downregulating gene expression; 4. Prions: infectious proteins viewed as epigenetic agents capable of inducing a phenotype without changing the genome.

Targets for  Chromatin/Epigenetics

Products for  Chromatin/Epigenetics

  1. Cat.No. Product Name Information
  2. GC12458 N-Oxalylglycine

    cell permeable inhibitor of α-ketoglutarate-dependent enzymes, including JMJD2A, JMJD2C, and JMJD2E.

     N-Oxalylglycine Chemical Structure
  3. GC40496 N6-Methyladenine N6-Methyladenine is a modified purine that is commonly found in genomes of prokaryotes, protists, and plants. N6-Methyladenine Chemical Structure
  4. GC17676 Nafamostat Broad spectrum serine protease inhibitor, kallikrein inhibitor Nafamostat Chemical Structure
  5. GC16290 Nafamostat hydrochloride Synthetic serine protease inhibitor Nafamostat hydrochloride Chemical Structure
  6. GC36690 Nampt-IN-3 Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death. Nampt-IN-3 Chemical Structure
  7. GC14562 Nanaomycin A A bacterial metabolite Nanaomycin A Chemical Structure
  8. GC10243 Nanaomycin C

    Amide of nanaomycin A

     Nanaomycin C Chemical Structure
  9. GC36691 Nanatinostat Nanatinostat (CHR-3996) is a potent, class I selective and orally active histone deacetylase (HDAC) inhibitor with an IC50 of 8 nM. Nanatinostat Chemical Structure
  10. GC61841 Naphthol AS-E Naphthol AS-E is a potent and cell-permeable inhibitor of KIX-KID interaction. Naphthol AS-E directly binds to the KIX domain of CBP (Kd:8.6 ?M), blocks the interaction between the KIX domain and the KID domain of CREB with IC50 of 2.26 ?M. Naphthol AS-E can be used for cancer research. Naphthol AS-E Chemical Structure
  11. GC65138 NCDM-32B NCDM-32B is a potent and selective KDM4 inhibitor that impaires viability and transforming phenotypes of breast cancer. NCDM-32B Chemical Structure
  12. GC19410 NCGC00244536

    NCGC00244536 is a potent KDM4B inhibitor with an IC50 of 10 nM

     NCGC00244536 Chemical Structure
  13. GC32896 NCGC00247743 NCGC00247743 is a histone lysine demethylase KDM4 inhibitor. NCGC00247743 Chemical Structure
  14. GC15536 NCH 51 An HDAC inhibitor NCH 51 Chemical Structure
  15. GC66329 NDI-034858 NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. NDI-034858 Chemical Structure
  16. GC65202 Nesuparib Nesuparib is a potent inhibitor of PARP. Nesuparib Chemical Structure
  17. GC13764 Nexturastat A HDAC6 inhibitor,highly potent and selective Nexturastat A Chemical Structure
  18. GC62620 NHWD-870 NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation. NHWD-870 Chemical Structure
  19. GC36734 NI-42 An inhibitor of the BRPF1 bromodomain NI-42 Chemical Structure
  20. GC16763 NI-57 bromodomains of BRPF proteins inhibitor NI-57 Chemical Structure
  21. GN10347 Nicotinamide (Vitamin B3)

    Nicotinamide is an inhibitor of poly(ADP-ribose) polymerase (PARP-1) enzymes.

     Nicotinamide (Vitamin B3) Chemical Structure
  22. GC44401 Nicotinamide riboside Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, is converted to bioavailable NAD+, via nicotinamide riboside kinase (NRK) and NMNAT, or by the action of nucleoside phosphorylase and NAM salvage. Nicotinamide riboside Chemical Structure
  23. GC36738 Nicotinamide riboside chloride

    A nicotinamide adenine dinucleotide (NAD[+]) precursor vitamin

     Nicotinamide riboside chloride Chemical Structure
  24. GC49270 Nicotinamide-d4 An internal standard for the quantification of nicotinamide Nicotinamide-d4 Chemical Structure
  25. GC62248 NiCur NiCur is a potent and selective CBP histone acetyltransferase (HAT) inhibitor with an IC50 value of 0.35 μΜ. NiCur, which blocks CBP HAT activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins. NiCur Chemical Structure
  26. GC34120 Niraparib R-enantiomer (MK 4827 (R-enantiomer)) Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent PARP1 inhibitor with IC50 of 2.4 nM. Niraparib R-enantiomer (MK 4827 (R-enantiomer)) Chemical Structure
  27. GC32964 NKL 22 A selective HDAC1/3 inhibitor NKL 22 Chemical Structure
  28. GC19264 NMS-P118 NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy. NMS-P118 Chemical Structure
  29. GC36751 NMS-P515 NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity. NMS-P515 Chemical Structure
  30. GC52166 NN-390 NN-390 is a potent and selective HDAC6 inhibitor, with an IC50 of 9.8 nM. NN-390 penetrates the blood-brain barrier (BBB). NN-390 shows study potential in metastatic Group 3 MB (medulloblastoma). NN-390 Chemical Structure
  31. GC48460 NR-160 An inhibitor of HDAC6 NR-160 Chemical Structure
  32. GC17762 NSC 33994 Selective inhibitor of JAK2 (IC50 = 60 nM). Displays no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM. NSC 33994 Chemical Structure
  33. GC15040 NSC 3852 A tumor cell differentiating agent NSC 3852 Chemical Structure
  34. GC50136 NSC 636819 KDM4A/KDM4B inhibitor NSC 636819 Chemical Structure
  35. GC14875 NSC 663284 Cdc25 dual specificity phosphatases inhibitor NSC 663284 Chemical Structure
  36. GC66049 NSC 694621 NSC 694621 is a potent PCAF inhibitor, with an IC50 of 5.71 μM (PCAF/H31-21). NSC 694621 exhibits good activity of inhibiting the proliferation of cancer cells. NSC 694621 Chemical Structure
  37. GC69597 NSC 694623

    NSC 694623 is an effective inhibitor of histone acetyltransferase (HAT), with an IC50 of 15.9 μM against recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has anti-proliferative activity in certain cancer cells and can be used for anticancer research.

     NSC 694623 Chemical Structure
  38. GC49412 NSC 756093 An inhibitor of the GBP1-Pim-1 protein-protein interaction NSC 756093 Chemical Structure
  39. GC11561 NSC 95397 Cdc25 dual specificity phosphatases inhibitor NSC 95397 Chemical Structure
  40. GC14103 NSC228155 EGFR activator NSC228155 Chemical Structure
  41. GC61142 NSC745885 NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple?cancer?cell lines but not normal cells.?NSC745885 is an effective?down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced?bladder?and oral squamous cell carcinoma (OSCC) cancers. NSC745885 Chemical Structure
  42. GC17775 NU 1025 An inhibitor of PARP NU 1025 Chemical Structure
  43. GC11972 NU 9056 Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively). NU 9056 Chemical Structure
  44. GC34692 NU6140 A Cdk2 inhibitor NU6140 Chemical Structure
  45. GC13925 Nullscript negative control of scriptaid, HDAC inhibitor Nullscript Chemical Structure
  46. GC64772 NV03 NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a Kd of 2.4 μM. NV03 has anticancer activity. NV03 Chemical Structure
  47. GC13229 NVP-BSK805

    A potent, selective JAK2 inhibitor

     NVP-BSK805 Chemical Structure
  48. GC36783 NVP-BSK805 dihydrochloride A potent, selective JAK2 inhibitor NVP-BSK805 dihydrochloride Chemical Structure
  49. GC17555 NVP-TNKS656 TNKS2 inhibitor NVP-TNKS656 Chemical Structure
  50. GC44477 NVS-CECR2-1 NVS-CECR2-1 is a potent inhibitor of CECR2 (cat eye syndrome chromosome region, candidate 2), a component of chromatin complexes that regulate gene expression controlling development. NVS-CECR2-1 Chemical Structure
  51. GC69601 OARV-771

    OARV-771 is a VHL-based BET degrader (PROTAC) with improved cell permeability. OARV-771 shows DC50 values of 6, 1, and 4 nM for Brd4, Brd2, and Brd3 respectively.

     OARV-771 Chemical Structure
  52. GC31677 Oclacitinib maleate (PF-03394197 maleate) Oclacitinib maleate (PF-03394197 maleate) (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) Chemical Structure
  53. GC17358 Octyl-α-ketoglutarate prolyl hydroxylases (PHD) activator Octyl-α-ketoglutarate Chemical Structure
  54. GC66067 ODM-207 ODM-207 (BET-IN-4) is a potent BET bromodomain protein (BRD4) inhibitor, with an IC50 of ≤ 1 μM. ODM-207 Chemical Structure
  55. GC17482 OF-1 BRPF1B and BRPF2 bromodomain inhibitor OF-1 Chemical Structure
  56. GC17314 OG-L002 LSD1 inhibitor,potent and specific OG-L002 Chemical Structure
  57. GC11792 OG-L002 HCl LSD1 inhibitor,potent and specific OG-L002 HCl Chemical Structure
  58. GC16397 OICR-9429 Wdr5-MLL interaction antagonist OICR-9429 Chemical Structure
  59. GC16958 Okadaic acid A potent inhibitor of protein phosphatases Okadaic acid Chemical Structure
  60. GC17580 Olaparib (AZD2281, Ku-0059436)

    A PARP inhibitor

     Olaparib (AZD2281, Ku-0059436) Chemical Structure
  61. GC69618 Olaparib-d8

    Olaparib-d8 is the deuterated form of Olaparib (AZD2281). Olaparib is an orally effective PARP inhibitor that inhibits PARP-1 and PARP-2 with IC50 values of 5 and 1 nM, respectively. Olaparib is also an activator of autophagy and mitophagy.

     Olaparib-d8 Chemical Structure
  62. GC49815 Oleuropein aglycone A polyphenol with diverse biological activities Oleuropein aglycone Chemical Structure
  63. GC12821 Oltipraz Nrf2 activator;An antischistosomal agent Oltipraz Chemical Structure
  64. GC67906 OM-153 OM-153 Chemical Structure
  65. GN10420 Ophiopogonin D' Ophiopogonin D' Chemical Structure
  66. GN10114 Oroxin A Oroxin A Chemical Structure
  67. GC41625 Oroxylin A

    Oroxylin A is a flavonoid that has been found in S.

     Oroxylin A Chemical Structure
  68. GC11360 ORY-1001 Selective inhibitor of KDM1A. ORY-1001 Chemical Structure
  69. GC36818 ORY-1001(trans) Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor. ORY-1001(trans) Chemical Structure
  70. GC32745 OSS_128167

    OSS_128167 is a potent selective silencing regulatory protein 6 (SIRT6) inhibitor with an IC50 of 89 μM. 

     OSS_128167 Chemical Structure
  71. GC69636 OTS193320

    OTS193320 is an imidazopyridine compound, a SUV39H2 methyltransferase activity inhibitor. OTS193320 reduces the global histone H3 lysine 9 trimethylation level in breast cancer cells and induces apoptosis cell death. Compared to single-agent OTS193320 or DOX, the combination of OTS193320 with Doxorubicin (DOX; A) can lead to a decrease in γ-H2AX levels and cancer cell viability.

     OTS193320 Chemical Structure
  72. GC17973 OTX-015 A BRD2, BRD3, and BRD4 inhibitor OTX-015 Chemical Structure
  73. GC45808 OUL35 An inhibitor of PARP10 OUL35 Chemical Structure
  74. GC17472 Oxamflatin HADC inhibitor Oxamflatin Chemical Structure
  75. GC14655 OXF BD 02 Selective inhibitor of the first bromodomain of BRD4 OXF BD 02 Chemical Structure
  76. GC39417 OXFBD04 OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166?nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity. OXFBD04 Chemical Structure
  77. GC41329 Pacritinib FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate cytokine signaling and are frequently mutated in cancers, particularly acute myeloid leukemia. Pacritinib Chemical Structure
  78. GC67873 PAD-IN-2 PAD-IN-2 Chemical Structure
  79. GC64367 PAD2-IN-1 PAD2-IN-1, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 Chemical Structure
  80. GC66335 PAD2-IN-1 hydrochloride PAD2-IN-1 hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold). PAD2-IN-1 hydrochloride Chemical Structure
  81. GN10452 Paeoniflorin Paeoniflorin Chemical Structure
  82. GC34071 Pamiparib (BGB-290) Pamiparib (BGB-290) (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib (BGB-290) has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor. Pamiparib (BGB-290) Chemical Structure
  83. GC12257 Panobinostat (LBH589) A pan-HDAC inhibitor Panobinostat (LBH589) Chemical Structure
  84. GC36855 Paris saponin VII Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia. Paris saponin VII Chemical Structure
  85. GC64579 PARP-1-IN-2 PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis. PARP-1-IN-2 Chemical Structure
  86. GC65927 PARP-2-IN-1 PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC50 of 11.5 nM. PARP-2-IN-1 Chemical Structure
  87. GC68006 PARP1-IN-11 PARP1-IN-11 Chemical Structure
  88. GC62275 PARP1-IN-5 dihydrochloride PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer. PARP1-IN-5 dihydrochloride Chemical Structure
  89. GC69660 PARP1-IN-7

    PARP1-IN-7 is an inhibitor of poly ADP-ribose polymerase-1 (PARP1), used as an anticancer agent.

     PARP1-IN-7 Chemical Structure
  90. GC64578 PARP1-IN-8 PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-8 Chemical Structure
  91. GC69657 PARP10-IN-2

    PARP10-IN-2 is an effective inhibitor of mono-ADP-ribosyltransferase PARP10, with an IC50 of 3.64 μM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 27 μM and 11 μM for human PARP2 and human PARP15, respectively.

     PARP10-IN-2 Chemical Structure
  92. GC69658 PARP10-IN-3

    PARP10-IN-3 is a selective mono-ADP-ribosyltransferase PARP10 inhibitor with an IC50 of 480 nM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 1.7 μM for both human PARP2 and human PARP15.

     PARP10-IN-3 Chemical Structure
  93. GC68035 PARP10/15-IN-1 PARP10/15-IN-1 Chemical Structure
  94. GC69655 PARP10/15-IN-2

    PARP10/15-IN-2 (Compound 8h) is an effective dual inhibitor of PARP10 and PARP15, with IC50 values of 0.15 μM and 0.37 μM, respectively. It can enter cells and prevent apoptosis.

     PARP10/15-IN-2 Chemical Structure
  95. GC69656 PARP10/15-IN-3

    PARP10/15-IN-3 (Compound 8a) is an effective dual inhibitor of PARP10 and PARP15, with IC50 values of 0.14 μM and 0.40 μM, respectively. It can enter cells and prevent apoptosis.

     PARP10/15-IN-3 Chemical Structure
  96. GC69659 PARP11 inhibitor ITK7

    PARP11 inhibitor ITK7 (ITK7) is an effective and selective inhibitor of PARP11. It can effectively inhibit PARP11 with an IC50 value of 14 nM. PARP11 inhibitor ITK7 can be used for research on cellular localization.

     PARP11 inhibitor ITK7 Chemical Structure
  97. GC39302 PARP14 inhibitor H10 PARP14 inhibitor H10, compound H 10, is a selective inhibitor against PARP14 (IC50=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis. PARP14 inhibitor H10 Chemical Structure
  98. GC69661 PARP7-IN-14

    PARP7-IN-14 (I-1) is an effective selective PARP7 inhibitor with an IC50 value of 7.6 nM. PARP7-IN-14 has anti-cancer activity.

     PARP7-IN-14 Chemical Structure
  99. GN10357 Parthenolide Parthenolide Chemical Structure
  100. GC15301 PBIT JARID1 family demethylases inhibitor PBIT Chemical Structure
  101. GC69669 PCAF-IN-2

    PCAF-IN-2 (compound 17) is an effective inhibitor of PCAF, with an IC50 value of 5.31 μM. PCAF-IN-2 exhibits anti-tumor activity and induces apoptosis and cell cycle arrest at the G2/M phase.

     PCAF-IN-2 Chemical Structure

Items 801 to 900 of 1280 total

per page
  2. 7
  3. 8
  4. 9
  5. 10
  6. 11

Set Descending Direction